title: Effect of steroids on energy expenditure and substrate oxidation in women with Crohn's disease.
abstract: OBJECTIVE
  Patients with Crohn's disease (CD) have increased energy expenditure and fat oxidation. Steroids, commonly used to treat flare-up of CD, induce weight gain. This study was designed to evaluate the effects of prednisone and budesonide on energy expenditure and substrate oxidation in patients with CD.
  
  
  METHODS
  Twenty-nine women with CD and 10 healthy controls were studied. Ten patients received prednisone (0.75-1.0 mg/kg/day), nine received budesonide (9 mg/ day), and 10 did not receive steroids. Resting energy expenditure and substrate oxidation were measured by indirect calorimetry in a fasting state and after a standard diet.
  
  
  RESULTS
  In the fasting state, resting energy expenditure was higher in patients without steroids than in the controls. Lipid oxidation was lower (p < 0.01) in patients with prednisone (0.46 +/- 0.39 mg/kg/min) than in patients with budesonide (0.97 +/- 0.28 mg/kg/min) and without steroids (1.06 +/- 0.32 mg/kg/min), but was similar with control subjects (0.47 +/- 0.20 mg/kg/min). Postprandially, lipid oxidation was lower (p < 0.01) in patients with prednisone (0.32 +/- 0.23 mg/kg/min) than in patients with budesonide (0.75 +/- 0.20 mg/kg/min), without steroids (0.82 +/- 0.23 mg/kg/min), and controls (0.58 +/- 0.15 mg/kg/min). Protein oxidation was significantly higher in patients with prednisone than in the other subjects.
  
  
  CONCLUSIONS
  In women with CD, prednisone decreases lipid oxidation and increases protein oxidation. These effects are not observed with budesonide and may contribute to the weight gain and side effects commonly observed with prednisone. A low-fat/high-protein diet could be proposed during a course of prednisone.
authors.forename: Rima
authors.initials: R
authors.lastname: Al-Jaouni
authors.forename: Stephane M
authors.initials: SM
authors.lastname: Schneider
authors.forename: Thierry
authors.initials: T
authors.lastname: Piche
authors.forename: Patrick
authors.initials: P
authors.lastname: Rampal
authors.forename: Xavier
authors.initials: X
authors.lastname: Hébuterne
mesh_terms: D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000494:pharmacology*; D001823:Body Composition; D019819:Budesonide / Q000008:administration & dosage / Q000494:pharmacology; D002153:Calorimetry, Indirect; D016022:Case-Control Studies; D003424:Crohn Disease / Q000188:drug therapy* / Q000378:metabolism*; D004334:Drug Administration Schedule; D004734:Energy Metabolism / Q000187:drug effects; D005260:Female; D006801:Humans; D015227:Lipid Peroxidation / Q000187:drug effects*; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage / Q000494:pharmacology; D011506:Proteins / Q000378:metabolism*; D015219:Substrate Cycling / Q000187:drug effects*
chemical_list: D000893:Anti-Inflammatory Agents; D011506:Proteins; D019819:Budesonide; D011241:Prednisone